Warning Letter: Wockhardt

News
Article

ePT--the Electronic Newsletter of Pharmaceutical Technology

On Feb. 21, the US Food and Drug Administration issued a warning letter to Wockhardt (Mumbai, India), a drug manufacturer. FDA cited the company for violations of CGMPs in the manufacture of drug products and active pharmaceutical ingredients.

On Feb. 21, the US Food and Drug Administration issued a warning letter (www.fda.gov/cder/warn/2006/320-06-01.pdf) to Wockhardt (Mumbai, India, www.wockhardt.com), a drug manufacturer. FDA cited the company for violations of CGMPs in the manufacture of drug products and active pharmaceutical ingredients. FDA discovered the violations during its inspection of Wockhardt's Aurangabad, India manufacturing facility in November 2005 and listed them in a Form 483 issued to the company. Wockhardt responded in a letter sent Dec. 7, but FDA found the response inadequate.

FDA claimed that the company did not always follow written production and process control procedures and document them at the time of performance. In particular, FDA alleged that Wockhardt violated the process validation protocol for certain tablets by taking samples outside the allowed range. The agency also stated that Wockhardt's control records did not include complete and accurate information relating to batch production and control, a violation that FDA described as "serious." According to the warning letter, the company's management admitted that inappropriate documentation practices such as back-dating and signing for actions not performed occurred at the facility. FDA gave Wockhardt 30 days to respond to the warning letter.

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes